The first breakthrough treatment for a rare, incurable brain cancer in more than 20 years will be listed on the PBS this week, saving patients tens of thousands of dollars.

The drug vorasdienib, sold as Voranigo, will be listed on the subsidised scheme for people living with IDH-mutant astrocytoma or oligodendroglioma.

A new drug for a rare brain cancer has been listed on the PBS. Mohammed Haneefa Nizamudeen

These brain tumours, while rare, are the most common malignant primary brain tumours in adults under 50, and affect an estimated 3230 Australians, according to Voranigo manufacturers Servier.

Patients are typically diagnosed between the ages of 20 and 45, with symptoms escalating over many years including seizures, cognitive changes, physical disability, and loss of independence.

Prior to this new drug being approved, patient options were limited to surgery, ongoing monitoring, and radiotherapy or chemotherapy to slow its progression.

There is no cure.

The PBS listing means patients will pay a maximum of $25 per script, or $7.70 with a concession card, for a medicine that would otherwise cost tens of thousands of dollars a month.

Vorasidenib can be used to treat cancers with mutations in the IDH1 or IDH 2 genes that cause abnormal proteins to form, which in turn contribute to cancer growth.

The drug blocks the mutated proteins, which can slow or stop the cancer from growing.

“This is the first new treatment in 20 years being listed for a rare brain cancer, which can slow disease progression,” Health Minister Mark Butler said.

“Listing Voranigo will benefit around 135 Australians diagnosed with this rare, incurable brain cancer each year, offering these patients a treatment option that can give them precious time.”

Butler said without a PBS listing, patients would have to pay up to $28,000 for 30 days worth of the treatment.

“For people living with IDH-mutant glioma, managing the disease involves making complex treatment decisions over many years,” Peter MacCallum Cancer Centre medical oncologist Associate Professor Jim Whittle said.

“Caring for these patients often involves balancing long-term disease control with preserving neurological function and quality of life.”

He said the addition of vorasidenib to the PBS provided more choice to patients battling the disease.

Australian Brain Tumour Collaborative spokesperson Craig Cardinal said the listing was a “significant milestone”.

“Access to treatment is only one part of the journey.,” he said.

“People living with brain cancer and their families also need coordinated multidisciplinary care, psychosocial support and practical services throughout every stage of their diagnosis.”

Servier Australia and New Zealand general manager Mélanie Chamaux said the company was proud to see Voranigo listed on the PBS.

The drug will allow more options for doctors and patients. Getty

“The listing represents a collective achievement of the healthcare system recognising therapeutic progress and the meaningful difference innovative medicines can make for patients, their families and the broader community,” she said.

“We hope this milestone brings renewed confidence and optimism to those facing the challenges of this disease.”

Vorasdienib can result in increased liver enzymes, with other side effects including fatigue, headache, diarrhoea, nausea, muscle ages, and stiffness.

Servier guidelines say liver function should be monitored before and throughout treatment.

Patients should consult their specialist about their treatment options.